Concepedia

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Yukio Tanizawa, Kohei Kaku, Eiichi Araki, Kazuyuki Tobe, Yasuo Terauchi, Kazunori Utsunomiya, Yasuhiko Iwamoto, Hirotaka Watada, Wataru Ohtsuka, Daisuke Watanabe,

Expert Opinion on Pharmacotherapy · 2014 · 80 citations · 14 references

DOI

Abstract

Tofogliflozin was well tolerated and showed sustained efficacy in both trials.

References

14

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Jan Bolinder, Östen Ljunggren, Joel Kullberg et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 849 citations

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Clifford J. Bailey, Jorge Luiz Gross, Anne Pieters et al. · The Lancet · 2010 · 848 citations

, , +6

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

Ele Ferrannini, Silvia Ramos, Afshin Salsali et al. · Diabetes Care · 2010 · 700 citations · Full text

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

James F. List, Vincent Woo, Enrique Morales et al. · Diabetes Care · 2008 · 689 citations · Full text

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Y. Kanai, W S Lee, Dennis Brown et al. · Journal of Clinical Investigation · 1994 · 619 citations · Full text

, , +20